Recent publications published by researchers at the MRC WIMM.
CD34+CD19-CD22+ B-cell progenitors might underlie phenotypic escape in patients treated with CD19-directed therapies.
Journal article
Bueno C. et al, (2022), Blood
Longitudinal and Individual Symptom Analyses of Momelotinib and Ruxolitinib-Treated Myelofibrosis Patients from SIMPLIFY-1
Conference paper
Mesa R. et al, (2022), BRITISH JOURNAL OF HAEMATOLOGY, 197, 79 - 80
A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
Journal article
Mead AJ. et al, (2022), Therapeutic Advances in Hematology, 13
A Randomized, Phase 3, Trial of Interferon-α versus Hydroxyurea in Polycythemia Vera and Essential Thrombocythemia.
Journal article
Mascarenhas J. et al, (2022), Blood
Ezh2 is essential for the generation of functional yolk sac derived erythro-myeloid progenitors.
Journal article
Neo WH. et al, (2021), Nat Commun, 12
A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program.
Journal article
Rice S. et al, (2021), Nat Commun, 12
CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) PROTEIN INHIBITOR, IN COMBINATION WITH RUXOLITINIB, IN JAK INHIBITOR-NAIVE MYELOFIBROSIS PATIENTS: UPDATE OF MANIFEST PHASE 2 STUDY
Conference paper
Palandri F. et al, (2021), HAEMATOLOGICA, 106, 5 - 6
THE BET INHIBITOR, CPI-0610, PROMOTES MYELOID DIFFERENTIATION IN MYELOFIBROSIS (MF) PATIENT BONE MARROW AND PERIPHERAL CD34+HEMATOPOIETIC STEM CELLS
Conference paper
Vannucchi A. et al, (2021), HAEMATOLOGICA, 106, 51 - 51
Transitions in lineage specification and gene regulatory networks in hematopoietic stem/progenitor cells over human development.
Journal article
Roy A. et al, (2021), Cell Rep, 36
Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemia.
Journal article
Iskander D. et al, (2021), Sci Transl Med, 13
Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study
Conference paper
Gupta V. et al, (2021), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21, S362 - S362
Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis Patients
Conference paper
Mesa R. et al, (2021), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21, S360 - S360
The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders.
Journal article
Cross NCP. et al, (2021), British journal of haematology
Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.
Journal article
Chowdhury O. et al, (2021), Br J Haematol
Familial thrombocytopenia: The long and short of it.
Journal article
Murphy L. and Mead AJ., (2021), J Exp Med, 218
BEYOND A BINARY ENDPOINT: LONGITUDINAL AND INDIVIDUAL SYMPTOM ANALYSES FROM THE SIMPLIFY-1 STUDY DEMONSTRATE CLINICALLY COMPARABLE SYMPTOMATIC BENEFIT OF MOMELOTINIB TO RUXOLITINIB IN JAK INHIBITOR NAIVE MYELOFIBROSIS PATIENTS
Conference paper
Mesa R. et al, (2021), VALUE IN HEALTH, 24, S22 - S22
Longitudinal and individual symptom analyses of momelotinib and ruxolitinib treated myelofibrosis patients from SIMPLIFY-1.
Conference paper
Mesa RA. et al, (2021), JOURNAL OF CLINICAL ONCOLOGY, 39
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
Journal article
Ahern DJ. et al, (2021)
Developmental stage- and site-specific transitions in lineage specification and gene regulatory networks in human hematopoietic stem and progenitor cells
Journal article
ROY A. et al, (2021), bioRxiv
Application of Single-Cell Approaches to Study Myeloproliferative Neoplasm
Journal article
Royston D. et al, (2021), HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 35, 279 - 293